CA-TIGO
Tigo Energy, Inc. , the solar industry’s leading Flex MLPE (Module Level Power Electronics) supplier, today revealed that one of the Company’s solar systems in the Netherlands consistently produces 30% more energy by using Tigo MLPE Optimizers. The drastic increase in energy production was measured on a per-module basis by the Tigo EI software using the exclusive Reclaimed Energy feature. Solar installers planning to attend Solar Solutions International 2022 in Vijfhuizen are invited to meet with Tigo representatives to discuss hardware and software solutions like those used in this installation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220406005028/en/
The 12kWp solar system was designed and installed by homeowner Hans de Git, an energy consultant at NL HDG Energie Advies. The array spans five different roof orientations on the residence in North Holland and combines Tigo TS4-A-O optimizers with a Cloud Connect Advanced (CCA) datalogger and Tigo Access Point (TAP) antennas to enable rapid shutdown, module-level visibility, and Reclaimed Energy optimization. This universal system architecture is powered by Tigo EI software and eliminates the complications of mismatches caused by varied module orientations as well as variations in module output and inverter characteristics. Over the last two years, the system has generated 5MWh of clean energy, of which 1.5MWh represented reclaimed energy provided by the Tigo TS4-A-O optimizers.
“We started using Tigo in 2012, and we have become great fans of the Tigo family of solar MLPE optimizers because they bring benefits to us as the installer and our customers,” said Mr. de Git. “When it came time to choose equipment for a new PV installation on my own house, I didn’t hesitate to choose Tigo again. Because of the specific layout of the array, I would have needed at least five MPPTs to make it work properly, which would have meant adding at least one more inverter. With the Tigo TS4 platform, I avoided the expense of additional inverters, and I can now fully exploit the double MPP tracker of my string inverter.”
“Hearing about the success of Mr. de Git is what the solar industry is all about for me,” said Jaap van Kriekingen, business development manager for Benelux at Tigo Energy. “Tigo EI software provides a clear visual readout of energy production for homeowners, allowing them to see the benefits brought by optimization over time. This level of down-to-the-hour visualization provides the peace of mind that their PV systems are performing at their very best.”
Both Jaap van Kriekingen and Mirko Bindi, Tigo VP EMEA Sales and MD Europe, respectively, will be present at the Solar Solutions International at Expo Haarlemmermeer in Vijfhuizen, the Netherlands, from April 12-14, 2022 at IBC Solar B.V. booth nr B11.1. IBC Solar, which produces tailor-made solutions ranging from small residential PV plants to major solar projects in the Benelux region, will introduce its new AeroFix G3 mounting system at the expo.
To learn more about the Tigo TS4 platform and its exclusive Reclaimed Energy feature, read the latest case study or visit www.tigoenergy.com/ts4 .
About Tigo Energy
Tigo Energy, the worldwide leader in Flex MLPE (Module Level Power Electronics), designs innovative solar power conversion and storage products that provide customers more choice and flexibility. The Tigo TS4 platform increases solar production, decreases operating costs, and enhances safety. When combined with the Tigo Energy Intelligence (EI) platform, it delivers module, system, and fleet-level insights to maximize solar performance and minimize operating costs. The Tigo EI Residential Solar Solution , a flexible solar-plus-storage solution for home installations, rounds out the Company’s portfolio of solar energy technology. Tigo was founded in Silicon Valley in 2007 to accelerate the adoption of solar energy, and its global team supports customers whose systems reliably produce gigawatt-hours of safe solar energy on seven continents. Find us online at www.tigoenergy.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005028/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom